| 000 | 01728 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516184027.0 | ||
| 264 | 0 | _c20140922 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a1879-0828 | ||
| 024 | 7 |
_a10.1016/j.ejim.2013.11.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIurlo, Alessandra | |
| 245 | 0 | 0 |
_aComorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. _h[electronic resource] |
| 260 |
_bEuropean journal of internal medicine _cJan 2014 |
||
| 300 |
_a63-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzamides _xtherapeutic use |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aUbertis, Anna | |
| 700 | 1 | _aArtuso, Silvia | |
| 700 | 1 | _aBucelli, Cristina | |
| 700 | 1 | _aRadice, Tommaso | |
| 700 | 1 | _aZappa, Manuela | |
| 700 | 1 | _aCattaneo, Daniele | |
| 700 | 1 | _aMari, Daniela | |
| 700 | 1 | _aCortelezzi, Agostino | |
| 773 | 0 |
_tEuropean journal of internal medicine _gvol. 25 _gno. 1 _gp. 63-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejim.2013.11.002 _zAvailable from publisher's website |
| 999 |
_c23339809 _d23339809 |
||